Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$2.04 - $4.17 $22,440 - $45,870
11,000 New
11,000 $24,000
Q4 2023

Jan 23, 2024

BUY
$1.33 - $2.88 $14,630 - $31,680
11,000 New
11,000 $19,000
Q1 2023

Apr 20, 2023

BUY
$0.65 - $2.3 $7,150 - $25,299
11,000 New
11,000 $8,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $73M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Camelot Portfolios, LLC Portfolio

Follow Camelot Portfolios, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camelot Portfolios, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Camelot Portfolios, LLC with notifications on news.